DRI Healthcare Trust is managed by DRI Capital Inc. (“DRI”) a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and have deployed more than $2 billion, acquiring more than 60 royalties on 40-plus drugs. By identifying and acquiring interests in medicines with a focus on those that effectively treat and address unmet medical needs, DRI also provides an engine for investors seeking exposure to the demand- and innovation-driven growth trends in the biopharma industry while limiting the risks and costs connected to drug development. In 2021, DRI transitioned to a public company structure through the listing of DRI Healthcare Trust on the Toronto Stock Exchange under “DHT.UN” in Canadian dollars and under “DHT.U” in U.S. dollars. Building on DRI’s history of acquiring high-quality assets, we continue to concentrate on medicines that matter – pursuing deals for long-duration commercial assets that provide significant clinical benefits.
DRI Capital is a pioneer and global leader in healthcare royalty investing with over two decades of experience. Since 2006, DRI, through its managed funds, has acquired over $2 billion in royalty streams on some of the world’s best-selling pharmaceutical products. DRI’s funds have collectively acquired over 60 separate royalty streams from inventors, academic and research institutions and life sciences companies, leading the way in the industry with numerous milestone transactions. In 2021, DRI took DRI Healthcare Trust public in the Toronto Stock Exchange.